A network for sharing data and resources in immuno-oncology
Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI
This study is all about finding better ways to use immune treatments for cancer by working together to understand why some patients don’t respond, discovering new targets for these treatments, and identifying helpful markers that can predict how well they might work, all to help adults with cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10455318 on NIH RePORTER |
What this research studies
This research focuses on enhancing the clinical use of immuno-oncology strategies by collaborating to understand resistance mechanisms, discover new immune targets, and identify predictive biomarkers. A multidisciplinary team will support various components of the Immuno-Oncology Translation Network (IOTN) to evaluate combination therapies and develop preventive approaches against cancers in adults. The project aims to streamline data management and analysis to improve the efficiency and effectiveness of cancer research efforts.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with cancer who may benefit from innovative immunotherapy approaches.
Not a fit: Patients with non-malignant conditions or those who are not adults may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments and preventive strategies for cancer patients.
How similar studies have performed: Previous research in immuno-oncology has shown promising results, indicating that collaborative approaches can lead to significant advancements in cancer treatment.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Hutson, Alan David — Roswell Park Cancer Institute Corp
- Study coordinator: Hutson, Alan David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.